Resources
Menu
Close
Resources
Contact us
Oral solid dose
Sterile injectables
Antibody-drug conjugates
Tech transfer
OSD manufacturing
SI manufacturing
ADC manufacturing
Careers
Leadership team
Regulatory support
Sustainability
IP protection
Expert insights
“In Safe Hands” Pharma Tech - 30 year anniversary Q&A
It has been widely reported that the number of highly complex and potent molecules entering development is rising, particularly in lieu of the fact that the bio/pharma industry is leaning towards personalized therapeutic offerings and drug development for orphan diseases.
Pharmaceutical Technology Europe caught up with JoyL Silva, General Manager of Pfizer CentreOne regarding the trends in the contract development and manufacturing organization (CDMO) sector working with complex molecules and the benefits of the embedded model.
Success
Thank you, your submission has been received!
Latest marketing updates
Let’s stay in touch
Pfizer CentreOne would like to send you information which we believe may be of value to you and relevant to your work. If you would like to receive such information, please tick the box below.
BY TICKING THE BOX AND CLICKING “LET’S COLLABORATE” BELOW, I CONSENT TO RECEIVING THOUGHT LEADERSHIP, INDUSTRY NEWS, AND INVITATIONS BY EMAIL OR OTHER ELECTRONIC MEANS, WHICH PFIZER CENTREONE BELIEVES MAY BE OF VALUE TO ME, RELEVANT TO MY WORK AND TAILORED TO MY PROFESSIONAL PROFILE AND INTERESTS. THIS MAY INCLUDE PROMOTIONAL INFORMATION ON PRODUCTS, SERVICES AND EVENTS PROVIDED OR ORGANIZED BY PFIZER CENTREONE.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Let's Collaborate
A CMO for therapies that define legacies
Follow us
Latest marketing updates
Sign up
© 2025 Pfizer Inc. All rights reserved. Pfizer CentreOne is a registered trademark of Pfizer Inc. Privacy Policy | Terms of Use